We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Screening of mutations in the additional sex combs like 1, transcriptional regulator, tumor protein p53, and KRAS proto-oncogene, GTPase/NRAS proto-oncogene, GTPase genes of patients with myelodysplastic syndrome.
- Authors
LEITE, CAROLINA; DELMONICO, LUCAS; ALVES, GILDA; GOMES, ROMARIO JOSÉ; MARTINO, MARIANA RODRIGUES; DA SILVA, ALINE RODRIGUES; DOS SANTOS MOREIRA, ALINE; MAIOLI, MARIA CHRISTINA; SCHERRER, LUCIANO RIOS; BASTOS, ELENICE FERREIRA; IRINEU, ROBERTO; ORNELLAS, MARIA HELENA
- Abstract
Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal bone marrow disorders characterized by ineffective hematopoiesis, different degrees of cellular dysplasia, and increased risk of progression to acute myeloid leukemia. International Prognostic Scoring System is the gold standard for MDS classification; however, patients exhibiting different clinical behaviors often coexist in the same group, indicating that the currently available scoring systems are insufficient. The genes that have recently been identified as mutated in MDS, including additional sex combs like 1, transcriptional regulator (ASXL1), tumor protein p53 (TP53), and KRAS proto-oncogene and GTPase (KRAS)/NRAS proto-oncogene, GTPase (NRAS), may contribute to a more comprehensive classification, as well as to the prognosis and progression of the disease. In the present study, the mutations in the ASXL1, TP53 and NRAS/KRAS genes in 50 patients were evaluated by sequencing genomic bone marrow DNA. Nine patients (18%) presented with at least one type of mutation. Mutations in TP53 were the most frequent in six patients (12%), followed by ASXL1 in two patients (4%) and NRAS in one patient (2%). The nine mutations were detected in patients with low- and high-risk MDS. The screening of mutations in MDS cases contributes to the application of personalized medicine.
- Subjects
MYELODYSPLASTIC syndromes; GENETIC mutation; GENETIC transcription regulation; TUMOR proteins; P53 antioncogene; PROTO-oncogenes; GUANOSINE triphosphatase; PATIENTS
- Publication
Biomedical Reports, 2017, Vol 7, Issue 4, p343
- ISSN
2049-9434
- Publication type
Article
- DOI
10.3892/br.2017.965